10.02.25 -- Execute Or Decay: Radiopharma's Outsourcing Reality

Explore the pivotal role of CDMOs in developing and manufacturing antibody-drug conjugates (ADCs) at the ADC session of the Outsourced Pharma Capacity Update on Oct. 6. This virtual event features brief, interactive presentations showcasing available CDMO capabilities and capacity for these targeted cancer therapies. Engage directly with suppliers to assess fit for your pipeline needs — all from your computer. Open to biopharma professionals, consultants, and investors seeking strategic CDMO partnerships. Save your spot today!

Discover how to effectively navigate the transition to GMP, ensuring your project meets stringent requirements while streamlining development and minimizing risk.

When transitioning from a vial to a combination product system, the best approach is to have a holistic de-risk strategy with an intentional focus on the patient, the plan, and the product.

Whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, see how the right system can be tailored to meet the needs of each unique biologic.

A European consortium achieved greater T cell expansion compared to baseline conditions using real-time process monitoring and control.

Explore key factors in selecting the right CDMO partner for cell line development, including expertise in host cell background, preparation for complex protein production, and de-risking manufacturing.

Once you've identified a CMO partner, how do you ensure success? The secret: planning as early as possible – while your product is still in preclinical or clinical development.

Optimize your validation strategy to meet evolving regulatory demands and product complexities with a scalable, efficient framework that accelerates facility readiness and ensures consistent quality.

Uncover how this CHO AOF panel that provides rapid detection of relevant adventitious viral contaminants in bulk harvest material, and data showing equivalent sensitivity to the in vitro assay.

This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.

Speeding up the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for studies.

The ability to administer high doses of biologics subcutaneously offers numerous benefits, including reduced treatment burden, improved patient convenience, and increased adherence to treatments.

Advance biopharmaceutical development with robust HCP detection strategies and high-quality antibody reagents to ensure product purity, safety, and regulatory compliance.

With cutting-edge innovations like smart glasses for live process insights and a data-sharing portal, we're able to provide the capacity and expertise to bring biologics to commercial success.

We've curated a powerful global network of 3,700+, with 29 global locations. Our integrated solutions and capabilities bridge discovery, engineering, development, and manufacturing across sites.